Fig. 6

Correlation between the expression levels of potential prognostic biomarkers (DOE-A genes) and patient survival. A–D Relapse-free, overall, distant metastasis-free, and post-progression survival of four DOE-A genes (CCNA2 in A; CENPN in B; DEPDC1 in C; TTK in D) were stratified by the expression levels of each gene (low or high). Expression data were analyzed using KM plotter (http://kmplot.com/). JetSet best probes were selected and patients (for CCNA2, N = 3951 in RFS, = 1402 in OS, = 1746 in DMFS and = 414 in PPS; for CENPN, N = 1764 in RFS, = 626 in OS, = 664 in DMFS and = 173 in PPS; for DEPDC1, N = 1764 in = RFS, = 626 in OS, = 664 in DMFS and = 173 in PPS; for TTK, N = 3951 in RFS, = 1402 in OS, = 1746 in DMFS and = 414 in PPS) were split by median expression. NS, not significant. E Metastatic relapse-free survival of four DOE-A genes were stratified by the expression levels of each gene (low or high). Microarray expression data were analyzed using bc-GenExMiner v4.3 (http://bcgenex.centregauducheau.fr/). Patients (for CCNA2 and TTK, N = 4533; for CENPN and DEPDC1, N = 4359) were split by median expression. Statistical analyses were performed by pre-set analytic methods. HRs (hazardous ratios) and 95% CIs (confidence intervals) are indicated